LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 3 of 15: Cell count and relative growth within biological replicate 3. - Dataset (ID:20239)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Dasatinib | 3.33 | uM | LJP6 | 1 | I02 | 72 | hr | 1401 | 2194 | 4223 | 0.5195 | 0.2809 |
| SK-BR-3 | Dasatinib | 3.33 | uM | LJP6 | 2 | I02 | 72 | hr | 1401 | 2878 | 4223 | 0.6815 | 0.5233 |
| SK-BR-3 | Dasatinib | 3.33 | uM | LJP6 | 3 | I02 | 72 | hr | 1401 | 2378 | 4223 | 0.5631 | 0.3461 |
| SK-BR-3 | Dovitinib | 3.33 | uM | LJP5 | 1 | E20 | 72 | hr | 1401 | 2051 | 4223 | 0.4857 | 0.2302 |
| SK-BR-3 | Dovitinib | 3.33 | uM | LJP5 | 2 | E20 | 72 | hr | 1401 | 2209 | 4223 | 0.5231 | 0.2862 |
| SK-BR-3 | Dovitinib | 3.33 | uM | LJP5 | 3 | E20 | 72 | hr | 1401 | 2065 | 4223 | 0.4890 | 0.2351 |
| SK-BR-3 | Enzastaurin | 3.33 | uM | LJP5 | 1 | D14 | 72 | hr | 1401 | 4308 | 4223 | 1.0201 | 1.0301 |
| SK-BR-3 | Enzastaurin | 3.33 | uM | LJP5 | 2 | D14 | 72 | hr | 1401 | 4724 | 4223 | 1.1186 | 1.1775 |
| SK-BR-3 | Enzastaurin | 3.33 | uM | LJP5 | 3 | D14 | 72 | hr | 1401 | 4720 | 4223 | 1.1177 | 1.1761 |
| SK-BR-3 | Erlotinib | 3.33 | uM | LJP5 | 1 | M20 | 72 | hr | 1401 | 3419 | 4223 | 0.8096 | 0.7150 |
| SK-BR-3 | Erlotinib | 3.33 | uM | LJP5 | 2 | M20 | 72 | hr | 1401 | 3848 | 4223 | 0.9112 | 0.8671 |
| SK-BR-3 | Erlotinib | 3.33 | uM | LJP5 | 3 | M20 | 72 | hr | 1401 | 3897 | 4223 | 0.9228 | 0.8844 |
| SK-BR-3 | Foretinib | 3.33 | uM | LJP5 | 1 | H08 | 72 | hr | 1401 | 1461 | 4223 | 0.3460 | 0.0211 |
| SK-BR-3 | Foretinib | 3.33 | uM | LJP5 | 2 | H08 | 72 | hr | 1401 | 1372 | 4223 | 0.3249 | -0.0105 |
| SK-BR-3 | Foretinib | 3.33 | uM | LJP5 | 3 | H08 | 72 | hr | 1401 | 1624 | 4223 | 0.3846 | 0.0788 |
| SK-BR-3 | R406 | 3.33 | uM | LJP6 | 1 | C14 | 72 | hr | 1401 | 4750 | 4223 | 1.1248 | 1.1867 |
| SK-BR-3 | R406 | 3.33 | uM | LJP6 | 2 | C14 | 72 | hr | 1401 | 4683 | 4223 | 1.1089 | 1.1630 |
| SK-BR-3 | R406 | 3.33 | uM | LJP6 | 3 | C14 | 72 | hr | 1401 | 4151 | 4223 | 0.9829 | 0.9745 |
| SK-BR-3 | Pictilisib | 3.33 | uM | LJP6 | 1 | D20 | 72 | hr | 1401 | 1544 | 4223 | 0.3656 | 0.0505 |
| SK-BR-3 | Pictilisib | 3.33 | uM | LJP6 | 2 | D20 | 72 | hr | 1401 | 1565 | 4223 | 0.3706 | 0.0579 |
| SK-BR-3 | Pictilisib | 3.33 | uM | LJP6 | 3 | D20 | 72 | hr | 1401 | 1619 | 4223 | 0.3834 | 0.0771 |
| SK-BR-3 | Gefitinib | 3.33 | uM | LJP6 | 1 | N08 | 72 | hr | 1401 | 2524 | 4223 | 0.5977 | 0.3978 |
| SK-BR-3 | Gefitinib | 3.33 | uM | LJP6 | 2 | N08 | 72 | hr | 1401 | 2536 | 4223 | 0.6005 | 0.4021 |
| SK-BR-3 | Gefitinib | 3.33 | uM | LJP6 | 3 | N08 | 72 | hr | 1401 | 2738 | 4223 | 0.6483 | 0.4737 |
| SK-BR-3 | Geldanamycin | 3.33 | uM | LJP5 | 1 | O02 | 72 | hr | 1401 | 642 | 4223 | 0.1520 | -0.2692 |